



December 20, 2016

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2007-003134-42/ Novartis Protocol ID CELC200AUS15

*A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentials (ERPs) in Patients with Idiopathic Parkinson's Disease and End-of-Dose Wearing Off.*

Trial CELC200AUS15 was cancelled with no patient enrollment and as such, no results will be reported.